NON-MUSCLE INVASIVE BLADDER CANCER

This study is testing an investigational drug called TYRA300 for people with advanced bladder cancer and other solid tumors that have specific changes in a gene called FGFR3. The main goals are to find a safe and effective dose and to see if the drug can shrink or control the tum…

This large, global study is testing whether adding a new immunotherapy drug called durvalumab to the standard BCG treatment works better than BCG alone for people with high-risk bladder cancer that hasn't spread into the muscle wall. The main goal is to see if the combination hel…

This study is testing a new treatment called cretostimogene to see if it can prevent intermediate-risk bladder cancer from returning after tumor removal surgery. About 367 participants will be randomly assigned to receive either the new treatment or standard observation with regu…

This study is testing a combination of two treatments—the standard BCG therapy and an immunotherapy drug called durvalumab—for adults with high-risk, early-stage bladder cancer that hasn't spread into the muscle wall. The goal is to see if this combination is safe and more effect…

This large study is testing if a combination of two chemotherapy drugs (gemcitabine and docetaxel) works as well as the standard BCG treatment for a specific type of bladder cancer. It involves about 870 adults with high-grade, non-muscle invasive bladder cancer who have not had …

This large, late-stage study is testing whether adding a new immunotherapy drug called sasanlimab to the standard BCG treatment works better than BCG alone for people with high-risk, early-stage bladder cancer. The main goal is to see if the combination helps keep the cancer from…

This early-stage study is testing the safety of an experimental treatment called CG0070 for people with intermediate-risk bladder cancer that hasn't spread into the muscle wall. After surgeons remove visible tumors, researchers will deliver CG0070 directly into the bladder to see…

This study is looking at a new way to predict if a common, low-risk form of bladder cancer will come back after surgery. Researchers are checking if a specific marker (SIX6) found in urine or tissue can tell which patients are at higher risk of recurrence. The goal is to help doc…

This study aims to help patients and doctors make better decisions when bladder cancer returns after initial treatment. Researchers are following 570 patients who choose either bladder removal surgery or additional drug therapy to see which approach leads to better quality of lif…